OCIPLA OCIPLA OCIPLA
  • Home
  • About
    • About OCIPLA
    • Committees
    • Past Presidents
    • Bylaws
  • Events
  • News
  • Membership
  • Contact
OCIPLA OCIPLA
  • Home
  • About
    • About OCIPLA
    • Committees
    • Past Presidents
    • Bylaws
  • Events
  • News
  • Membership
  • Contact
May 10

Federal Circuit Summaries (4 of 12)

  • May 10, 2022
  • staff
  • Uncategorized

Contributors: Akin Gump Strauss Hauer & Feld LLP

Silence May Support Negative Claim Limitation

In Novartis Pharmaceuticals v. Accord Healthcare Inc. Appeal No. 21-1070, the Federal Circuit held that a patent application that was silent about a “loading dose” of a drug provided written description support for a negative claim limitation requiring the absence of such a dose.

HEC Pharm Co., Ltd. and HEC Pharm USA Inc. (collectively, “HEC”) filed an Abbreviated New Drug Application (“ANDA”) for a generic drug to treat multiple sclerosis.  Novartis Pharmaceuticals Corp. (“Novartis”) sued HEC, alleging that HEC’s ANDA infringed U.S. Patent No. 9,187,405 (“the ’405 patent”).  The district court found that the ’405 patent was not invalid and that the ANDA infringed.  HEC appealed to the Federal Circuit, arguing that the ’405 patent was invalid because its claims violated the written description requirement of 35 U.S.C. § 112(a).

The Federal Circuit affirmed, finding sufficient written description support for excluding a “loading” (larger than normal) dose from the claimed treatment method.  The ’405 patent described dosing regimens for both an experiment on rats and a potential clinical trial on humans, without mentioning a loading dose for either regimen.  The Federal Circuit found no clear error in the district court’s finding, based on expert testimony, that these dosing regimens would have indicated to a person of ordinary skill that the claimed invention lacked a loading dose.

Chief Judge Moore dissented, arguing that the patent’s silence about loading doses could not support the negative limitation requiring their absence.

(Pharmaceuticals, Written description; Prepared by Nima Zargari)

Claim Element With No Antecedent Basis May Be Broader Than the Same Element With an Antecedent Basis.

In Evolusion Concepts, Inc. v. Hoc Events, Inc. Appeal No. 21-1963, the Federal Circuit held that a claim requiring the removal of a “factory-installed catch bar” before installation of “a catch bar” did exclude reuse of the original factory-installed bar.

Evolusion Concepts sued Juggernaut Tactical for infringement of a patent related to firearm magazine conversion kits.  On dueling motions for summary judgment of infringement and non-infringement, the parties disputed only whether the term “magazine catch bar” could encompass a factory-installed catch bar.  The district court relied on one sentence of the specification to conclude in Juggernaut’s favor that the claim excluded a factory-installed magazine catch bar: “The invention is a permanent fixture added to a semi-automatic firearm by removing the standard OEM magazine catch assembly and installing the invention.” Evolusion appealed.

On appeal, Juggernaut argued that the district court construction was correct and that the disputed term excluded factory-installed catch bars.  It argued that, because the claim used “a” before “magazine catch bar,” instead of antecedent-basis language such as “said” or “the,” the two magazine catch bars must be different. The Federal Circuit disagreed and reversed the district court’s grant of Juggernaut’s motion and denial of Evolusion’s.  The Federal Circuit explained that, under the ordinary meaning of “a magazine catch bar,” the bar could be “either the removed catch bar or a new or different catch bar.” 

(Firearms, Claim Construction, Summary Judgment; Prepared by Steven Friedland)

  • Facebook
  • Twitter
  • LinkedIn
  • E-Mail

Comments are closed.

Recent Posts

  • Federal Circuit Summaries (1 of 8)
  • Federal Circuit Summaries (2 of 8)
  • Federal Circuit Summaries (3 of 8)
  • Federal Circuit Summaries (4 of 8)
  • Federal Circuit Summaries (5 of 8)

Archives

  • January 2023
  • September 2022
  • May 2022
  • December 2021
  • November 2021
  • September 2021
  • August 2021
  • March 2021
  • December 2020
  • November 2020
  • September 2020
  • June 2020
  • April 2020
  • February 2020
  • September 2019
  • July 2019
  • June 2019
  • May 2019
  • April 2019
  • March 2019
  • January 2019
  • November 2018
  • September 2018
  • July 2018
  • June 2018
  • May 2018
  • March 2018
  • February 2018
  • December 2017
  • November 2017
  • October 2017
  • August 2017
  • July 2017
  • April 2017
  • February 2017
  • October 2016

Categories

  • Amicus Briefs
  • Copyright
  • Education and Training
  • Employment
  • Federal Circuit Summary
  • News
  • Non-Obviousness
  • Patent
  • Patent Trial and Appeal Board
  • Trade secret
  • Trademark
  • Uncategorized


Serving the Orange County Intellectual Property law community since 1983.

Orange County Intellectual Property Law Association
P.O. Box 7632
Newport Beach, CA 92658

About
Membership
Bylaws
Contact

© 2022 OCIPLA | All Rights Reserved | Website design by SafeHouse Web